ライフサイエンスコーパス: intravenous

1 We also compared our detailed intravenous (18)F-FDG dosimetry with older dosimetry dat

2 Oral (18)F-FDG is a palatable alternative to intravenous (18)F-FDG when venous access is problematic.

3 The patients underwent baseline PET/CT using intravenous (68)Ga-DOTATOC.

4 tudy participants received 74 MBq (2 mCi) of intravenous (89)Zr-DFO-daratumumab.

5 eive oral upadacitinib (15 mg once daily) or intravenous abatacept, each in combination with stable s

6 rticipants were randomized to receive either intravenous acetaminophen, 1 g (n = 289), or normal sali

7 went abdominal surgery, use of postoperative intravenous acetaminophen, compared with placebo, did no

8 exhibits desirable kidney distribution after intravenous administration and is fluorescent only after

9 ific retention of nanotherapeutics following intravenous administration as seen in the lung, liver, a

10 Upon intravenous administration of (64)Cu-Macrin in rabbits a

11 Here we show that, after intravenous administration of a collagen-binding domain

12 Current treatment involves intravenous administration of anti-inflammatory drugs wh

13 Intravenous administration of atorvastatin during MI lim

14 Here we show that intravenous administration of BCG profoundly alters the

15 ipants were randomly assigned to a 52-minute intravenous administration of ketamine (0.71 mg/kg, N=17

16 rapamycin (6 mg) or placebo 2 h prior to the intravenous administration of ketamine 0.5 mg/kg in a do

17 rapies for Gaucher disease include life-long intravenous administration of recombinant glucocerebrosi

18 he development of an aqueous formulation for intravenous administration of the drug at high dose, imp

19 rowth inhibition was seen after twice-weekly intravenous administration of the drug for three weeks (

20 rmacokinetic studies of released drugs after intravenous administration showed that the liver-to-plas

21 ous SNPs 466.0 +/- 86.0 nm) upon single dose intravenous administration to female and male BALB/c mic

22 Antibodies targeted the murine BBB after intravenous administration with one particular clone, 46

23 epatic metastases than patients who received intravenous administration, with a median intraarterial-

24 at levels roughly ten times lower than after intravenous administration.

25 It can offer several advantages over intravenous administration.

26 administered (18)F-FDG as an alternative to intravenous administration.

27 and >90 % excretion of QDs within 2 weeks of intravenous administration.

28 oxytocin is quantified after intranasal (not intravenous) administration in brain regions (orbitofron

29 gger anti-apoptotic pathway after repetitive intravenous administrations in mice.

30 n and dosimetry for (18)F-FDG after oral and intravenous administrations sequentially in the same sub

31 everal antibiotics with multi-month oral and intravenous administrations that are difficult to implem

32 The only available 2 treatment options are intravenous alteplase and endovascular therapy (mechanic

33 Endovascular thrombectomy with or without intravenous alteplase in acute stroke.

34 nset with a DWI-FLAIR or perfusion mismatch, intravenous alteplase resulted in better functional outc

35 Patients were stratified by intravenous alteplase treatment and declared endovascula

36 Randomised trials of intravenous alteplase versus standard of care or placebo

37 al was significantly higher in recipients of intravenous amiodarone (adjusted risk ratio, 1.26 [95% C

38 l anaesthetic wean as the discontinuation of intravenous anaesthesia without developing recurrent sta

39 We showcase these measures by comparison of intravenous and hindbrain routes of Mycobacterium marinu

40 wed that miR-18a reaches the brain following intravenous and intranasal administration.

41 Importantly, both intravenous and subcutaneous administrations of the fusi

42 almost 50 years after it was approved as an intravenous anesthetic.

43 ass index (+0.73 kg/m(2)), and a decrease in intravenous antibiotic courses by 35%.

44 mprovement in body mass index or decrease in intravenous antibiotic courses.Conclusions: Lumacaftor-i

45 trointestinal populations rapidly respond to intravenous antibiotic exposure.

46 adverse events between an initial course of intravenous antibiotic therapy and the addition of exten

47 V(1)% predicted rate of decline and rates of intravenous antibiotic use to treat pulmonary exacerbati

48 nt compared with 72/78 (92.3%) randomized to intravenous antibiotics (risk difference, 3.6%; 2-sided

49 Oral antibiotics were noninferior to intravenous antibiotics for the early treatment of KLA.

50 d for serious infections requiring prolonged intravenous antibiotics may face barriers to discharge,

51 t increase the risk of AKI compared to other intravenous antibiotics used for similar indication in t

52 5 days of hospitalization compared to other intravenous antibiotics used for similar indications.

53 Empirical intravenous antibiotics were administered in 21.1% of lo

54 fected necrosis is suspected, broad-spectrum intravenous antibiotics with ability to penetrate pancre

55 s managed conservatively with bowel rest and intravenous antibiotics.

56 iological treatment failure; and duration of intravenous antibiotics.

57 Treatment includes drainage and prolonged intravenous antibiotics.

58 esentation, 72.3% of episodes never required intravenous antibiotics.

59 ycemic clamp (100 and 300 mg/dL) followed by intravenous arginine bolus before and after 72-h glucose

60 Patients received neoadjuvant treatment with intravenous atezolizumab (1200 mg) on day 1, nab-paclita

61 assigned (1:1) to receive chemotherapy plus intravenous atezolizumab at 840 mg or placebo every 2 we

62 The finding that intravenous BCG prevents or substantially limits Mtb inf

63 All adult protocols recommend intravenous benzodiazepines (midazolam, n = 33; lorazepa

64 (2)) on day 1 and day 8, or gemcitabine plus intravenous berzosertib (210 mg/m(2)) on day 2 and day 9

65 re distributed in 3 arms (A): A1 received an intravenous bolus of atorvastatin during MI; A2 received

66 ial infarction, we demonstrate that a single intravenous bolus of n-apo AI (CSL111, 80 mg/kg) deliver

67 us of atorvastatin during MI; A2 received an intravenous bolus of vehicle during MI; and A3 received

68 Subcutaneous bortezomib has replaced intravenous bortezomib as it is associated with a more f

69 articipants underwent chelation therapy with intravenous CaNa(2)EDTA for 2 days followed by treatment

70 ts were randomly assigned (1:1:1) to receive intravenous carboplatin (area under the curve [AUC]5 or

71 every 21-day cycle (control group; group 1); intravenous carboplatin (AUC5 or AUC6) on day 1 and intr

72 :1) centrally using minimisation to group 1 (intravenous carboplatin area under the curve [AUC]5 or A

73 ents in the KRd group received 36 mg/m(2) of intravenous carfilzomib on days 1, 2, 8, 9, 15, and 16,

74 re randomized 1:1 to oral (ciprofloxacin) or intravenous (ceftriaxone) antibiotics for 28 days.

75 were randomly assigned 1:1 to receive either intravenous cetuximab 400 mg/m(2) 1 week before start of

76 nd increased spread into the brain following intravenous challenge, showing that meningeal IgA is ess

77 of RT followed by 250 mg/m(2)/wk, or weekly intravenous cisplatin 40 mg/m(2), during RT.

78 Male rats underwent intravenous cocaine self-administration (2 h/day) follow

79 he role of NPAS2 in drug taking, we measured intravenous cocaine self-administration (acquisition, do

80 he role of NPAS2 in drug taking, we measured intravenous cocaine self-administration in wild-type (WT

81 rague-Dawley rats trained to self-administer intravenous cocaine, we did transcriptome profiling of L

82 hrombus imaging (MRDTI), a technique without intravenous contrast and with a 10-minute acquisition ti

83 ng adenosine stress and at rest following an intravenous contrast bolus (0.05 mmol/kg, gadobutrol).

84 High quality computed tomography with intravenous contrast using a dual phase pancreatic proto

85 f colectomy, (6) optimal dosing regimens for intravenous corticosteroids and infliximab in these pati

86 f CSC in the right eye and the recent use of intravenous corticosteroids for bronchitis.

87 cks of size two, four, or six to receive six intravenous cycles of bevacizumab (15 mg/kg, day 1) plus

88 Healthy women received intravenous d6-alpha-tocopherol and consumed d3-alpha-to

89 Differential catabolism of the intravenous d6-alpha-tocopherol and oral d3-alpha-tocoph

90 e catabolized from administered oral d3- and intravenous d6-alpha-tocopherols.

91 Patients in the D-VMP group also received intravenous daratumumab (16 mg/kg of bodyweight, once we

92 In part 2 of GEN501, patients were given intravenous daratumumab 16 mg/kg once per week for 8 wee

93 Subcutaneous daratumumab was non-inferior to intravenous daratumumab in terms of efficacy and pharmac

94 nant human hyaluronidase PH20 or 16 mg/kg of intravenous daratumumab once weekly (cycles 1-2), every

95 o ten 21-day cycles of docetaxel (75 mg/m(2) intravenous, day 1) and prednisolone (5 mg twice daily,

96 geting and elimination of brain tumors after intravenous delivery and increased the survival of brain

97 gene expression following intra-tumoural and intravenous delivery in vivo.

98 n by assessing GFP expression after neonatal intravenous delivery of AAV8.

99 COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared wi

100 recent decompensation (HF hospitalization or intravenous diuretics for HF without hospitalization), a

101 ants, 203 were randomly assigned to a single intravenous dose of 800 mg iron-carboxymaltose and 202 t

102 e five arms in a 1:1:1:1:1 fashion: a single intravenous dose of ketamine 0.1 mg/kg (n = 18), a singl

103 At the highest intravenous dose used (24 mg/kg), in 5/6 sheep we observ

104 , and 15 of every 21-day cycle (group 2); or intravenous dose-fractionated carboplatin (AUC2) and int

105 nous carboplatin (AUC5 or AUC6) on day 1 and intravenous dose-fractionated paclitaxel (80 mg/m(2) by

106 ous dose-fractionated carboplatin (AUC2) and intravenous dose-fractionated paclitaxel (80 mg/m(2) by

107 prednisolone 0.5 to 1 mg/kg/day divided in 2 intravenous doses for 3 days.

108 crease in WI rates by giving 2 postoperative intravenous doses of Abx, suggesting postoperative Abx a

109 ical clearance data were generated following intravenous dosing in rats/NHPs and compared to the huma

110 rhosis, diabetes with chronic complications, intravenous drug use, radiation therapy, and solid organ

111 Treatment of melioidosis comprises intravenous drugs for at least 10 days, followed by oral

112 e-response or web-response system to receive intravenous durvalumab plus tremelimumab plus platinum-e

113 ences between the groups assigned to receive intravenous evinacumab at a dose of 15 mg per kilogram a

114 the efficacy and safety of subcutaneous and intravenous evinacumab, a fully human monoclonal antibod

115 luated serum phosphate for 28 days following intravenous FCM, and assessed associations with symptoms

116 risk factors for hypophosphataemia following intravenous ferric carboxymaltose (FCM) in patients with

117 ants were randomly assigned (1:1) to receive intravenous ferric carboxymaltose or placebo for up to 2

118 Both groups received 30 mg/m(2) intravenous fludarabine daily for 5 days (days -6 to -2)

119 Intravenous fluid (IVF) is a frequently recommended inte

120 mg/dL increase) concentrations, and initial intravenous fluid administration >=4 days following diar

121 (1.12 [1.02-1.23 per 1 mmol/L decrease), and intravenous fluid administration initiated >=4 days foll

122 Most common EMD interventions given were intravenous fluids 57 (21%), analgesia 49 (25%) and anti

123 ACU, during which 21 patients (11%) required intravenous fluids, 16 (9%) received antibiotics, 40 (22

124 Here, we report that an intravenous Follistatin gene delivery intervention with

125 ated, with no new safety concerns versus the intravenous formulation, and demonstrated robust hematol

126 receive ACR-designated group II or group III intravenous gadolinium-based contrast media (GBCM).

127 awasaki Disease including its treatment with intravenous gamma globulin treatment for which he receiv

128 ents were randomly assigned (1:1) to receive intravenous gemcitabine (1000 mg/m(2)) on day 1 and day

129 y minimal modeling from a frequently sampled intravenous glucose test, and red blood cell fatty acid

130 tabolism as assessed by a frequently sampled intravenous glucose tolerance test.RESULTSChronic mirabe

131 ubcutaneous group and 96 (37%) of 259 in the intravenous group (relative risk 1.11, 95% CI 0.89-1.37)

132 group (febrile neutropenia) and four in the intravenous group (sepsis [n=2], hepatitis B reactivatio

133 nts in the subcutaneous group and one in the intravenous group did not receive treatment and were not

134 randomly assigned (subcutaneous group n=263; intravenous group n=259).

135 in the subcutaneous group and 11 [4%] in the intravenous group).

136 bcutaneous group and 522 mug/mL (226) in the intravenous group.

137 ) in the oral group and 13/77 (16.9%) in the intravenous group.

138 loperidol, were randomly assigned to receive intravenous haloperidol dose escalation at 2 mg every 4

139 ed, affect brain oxygen responses induced by intravenous heroin at low, human-relevant doses.

140 eceptors at baseline (BASE) and following an intravenous hydrocortisone challenge (CORT) in 19 health

141 facilitate antitumor efficacy after systemic intravenous (i.v.) administration.

142 fore and after imaging who underwent CT with intravenous ICM or abdominal US (control group) between

143 have shown frequencies of AKI after CT with intravenous ICM to be similar to propensity score-matche

144 000 mg/m(2) for eight doses, with or without intravenous idarubicin (12 mg/m(2)) as a single dose, us

145 s who failed standard of care treatment with intravenous immune globulin + rituximab with or without

146 se of immunomodulating therapies was common: intravenous immune globulin was used in 144 (77%), gluco

147 mpared with intradermal or aerosol delivery, intravenous immunization induced substantially more anti

148 opag and 22 (61%) of 36 patients assigned to intravenous immunoglobulin (absolute risk difference 17.

149 sma collected pre- and postadministration of intravenous immunoglobulin (IVIG) from patients with gro

150 ebo-controlled trial to evaluate efficacy of intravenous immunoglobulin (IVIG) in reducing seizure fr

151 We report the effect of high-dose intravenous immunoglobulin (IVIg) on safety, tolerabilit

152 Corticosteroid and high-dose intravenous immunoglobulin achieved remission in 50% (n

153 Intravenous immunoglobulin and plasmapheresis (PLEX) hav

154 ed nonimmune were offered MMR vaccination or intravenous immunoglobulin depending on their transplant

155 Eltrombopag is an effective alternative to intravenous immunoglobulin for perioperative treatment o

156 Testing 54 intravenous immunoglobulin preparations, produced from p

157 Previous intravenous immunoglobulin within 2 weeks or thrombopoie

158 Intravenous immunoglobulin, steroids, and other immunomo

159 All patients received intravenous immunoglobulin, with adjunctive steroid ther

160 ndomly assigned: 38 to eltrombopag and 36 to intravenous immunoglobulin.

161 noadsorption, plasma exchange, and high-dose intravenous immunoglobulin.

162 s, and three of these patients also received intravenous immunoglobulin; one made a full recovery, 10

163 orticosteroids, dupilumab, interferon-gamma, intravenous immunoglobulins (IVIG), mepolizumab, methotr

164 posal in rats, pigs and dogs during constant intravenous infusion and euglycemic clamp conditions.

165 300 mg twice daily and durvalumab 1.5 g via intravenous infusion every 4 weeks until disease progres

166 ent was reported in 25 (10%) patients in the intravenous infusion group and 26 (10%) patients in the

167 se event that led to death (urosepsis in the intravenous infusion group and acute myocardial infarcti

168 neutropenia (34 [13%] of 252 patients in the intravenous infusion group vs 35 [14%] of 248 patients i

169 escalation of treatment in such cases using intravenous infusion of adrenaline which has been adopte

170 infusion of candesartan (4.2 mug kg(-1) ) or intravenous infusion of CAP (20 mg kg(-1) ).

171 stable lipid-lowering therapy to receive an intravenous infusion of evinacumab (at a dose of 15 mg p

172 on imaging through the imaging window during intravenous infusion of fluorescently labeled low and hi

173 Intravenous infusion of Ngb-H64Q-CCC restored respiratio

174 g healthy males: (1) NVC was assessed during intravenous infusion of saline (placebo) and the non-sel

175 with type 2 diabetes, we also observed that intravenous infusion of the same n-apo AI (CSL111, 80 mg

176 Intravenous infusion with either 5 mg of zoledronic acid

177 d through systemic administration (typically intravenous infusion), precluding the feasible dosing of

178 isotopic labeling with 1-(13) C(1) -acetate intravenous infusion, followed by measurement of labeled

179 ns including 750-1350 mg orally, or a 600-mg intravenous infusion.

180 hcare professional or self-administered) via intravenous infusion.

181 All other subjects received intravenous infusions of CYP-001 on days 0 and 7, at a d

182 practice are common in the administration of intravenous infusions, but not all result in negative co

183 practices and their effects on the safety of intravenous infusions.

184 o system-level resilience when administering intravenous infusions.

185 of inducing benefits peripherally following intravenous injection and in the brain at FUS-targeted a

186 magnetic drug targeting (MDT) through either intravenous injection and pulmonary delivery for lung ca

187 ere verified to traffic into the brain after intravenous injection in mice, and both cellular and in

188 arance of thrombolytics from blood following intravenous injection is a major clinical challenge in c

189 re obtained for 1 h beginning at the time of intravenous injection of (18)F-Gln.

190 were treated 13 d after engraftment with an intravenous injection of (212)Pb-daratumumab or control

191 Conclusion: Intravenous injection of (68)Ga-DOTA-Siglec-9 was safe a

192 An intravenous injection of 1.5 ml/kg of body mass of non-i

193 After intravenous injection of 100 MBq of the tracer, 4 succes

194 he technology involves HSPC mobilization and intravenous injection of an integrating HDAd5/35++ vecto

195 Anaphylaxis was induced by intravenous injection of antigen or anti-huIgE mAb.

196 lving men with severe hemophilia A, a single intravenous injection of BIVV001 resulted in high sustai

197 ted the endocochlear potential in vivo by an intravenous injection of furosemide and measured the vib

198 After a single intravenous injection of human CD34+ cells, NSG-SGM3 mic

199 ctor VIII activity, <1%) to receive a single intravenous injection of recombinant factor VIII at a do

200 perimental infection of GPgV in goslings via intravenous injection revealed robust replication and hi

201 Upon intravenous injection, the Ter119-NPs achieved remarkabl

202 elivery vehicle for Cre mRNA in vivo through intravenous injection, we achieved 8.2 % gene recombinat

203 were corroborated in a mouse model following intravenous injection, where active YAP increased the nu

204 body (89)Zr PET and (19)F MRI after a single intravenous injection.

205 peak organ activities occur later than after intravenous injection.

206 Bolus intravenous injections of microbubbles are standard prac

207 Intravenous injections of RNA-paclitaxel nanoparticles w

208 Intravenous injections of the PHP.eB-iMecp2 virus in sym

209 Here, we demonstrate that intravenous inoculation of SIV-infected macaques, a well

210 The study was underpowered to assess intravenous/intraosseous drug interactions, which were n

211 travenous nivolumab 3 mg/kg every 2 weeks or intravenous ipilimumab 10 mg/kg every 3 weeks for four d

212 sfusions in the placebo group and 105 in the intravenous iron group (rate ratio 0.98, 95% CI 0.68-1.4

213 Intravenous iron supplementation compared with placebo r

214 We investigated whether intravenous iron supplementation improves fatigue and ge

215 report evidence supporting repositioning of intravenous iron to the frontline in multiple disorders

216 Intravenous iron was administered as a single 1000 mg do

217 Preoperative intravenous iron was not superior to placebo to reduce n

218 who (1) completed a full course of inpatient intravenous (IV) antibiotics, (2) received a partial cou

219 tients, 9 had undergone an IR procedure with intravenous (IV) contrast <=22 days before infection.

220 CKD, and we summarize the available oral and intravenous (IV) iron formulations for the treatment of

221 Physician concerns about the safety of intravenous (IV) iron products and erythropoiesis-stimul

222 nal studies have raised concerns that giving intravenous (IV) iron to patients, such as individuals r

223 Intravenous (IV) succinate-induced PMN sequestration in

224 ed and has become a predictive tool to study intravenous (IV) therapeutic proteins.

225 ival difference, 5.5% [95% CI, 1.5-9.5]) and intravenous lidocaine (adjusted risk ratio, 1.21 [95% CI

226 Responders to intravenous lidocaine also had significantly greater mea

227 ypes between responders and nonresponders to intravenous lidocaine treatment using quantitative senso

228 el evaluated artifact production by using an intravenous line filled with fluids with varying concent

229 0:200) to determine the effect of taping the intravenous line to the patients' backs.

230 2 mmol/mL) and by positioning the simulated intravenous line within several fields of view (FOV) at

231 tem which allows patients to self-administer intravenous medications in small bolus doses.

232 The standardized clinical protocol was intravenous methyl prednisolone followed by/or oral pred

233 icosteroid taper therapy (PCT) consisting of intravenous methylprednisolone 1 gm daily for 1 week fol

234 ed with the off-label use of a perioperative intravenous n-3 PUFA emulsion as a standalone infusion i

235 astasized cancer were randomly assigned to 2 intravenous n-3 PUFA or saline control infusions the nig

236 to investigate the effects of perioperative intravenous n-3 PUFAs on inflammatory cytokines in colon

237 , placebo-controlled trial to assess whether intravenous NAC hastens liver recovery in hospitalized a

238 ents were randomly assigned (1:1) to receive intravenous nerinetide in a single dose of 2.6 mg/kg, up

239 Patients received intravenous nivolumab 3 mg/kg every 2 weeks or intraveno

240 ore surgical resection, followed by adjuvant intravenous nivolumab monotherapy for 1 year (240 mg eve

241 until completion of cycle 12; combined with intravenous obinutuzumab for six cycles starting with 10

242 SS score <=5) or TIA who were not undergoing intravenous or endovascular thrombolysis, the risk of th

243 from published rat and human data following intravenous or oral silver administration.

244 in (area under the curve [AUC]5 or AUC6) and intravenous paclitaxel (175 mg/m(2) by body surface area

245 Patients received neoadjuvant treatment with intravenous paclitaxel (200 mg/m(2)) and carboplatin (ar

246 der the curve [AUC]5 or AUC6 and 175 mg/m(2) intravenous paclitaxel every 3 weeks), group 2 (carbopla

247 ents were randomly assigned (2:1) to receive intravenous pembrolizumab (200 mg) or saline placebo eve

248 at was at the investigator's discretion, and intravenous pembrolizumab 200 mg every 3 weeks for up to

249 mance status score of 50 or higher, received intravenous pembrolizumab at an initial dose of 2 mg/kg

250 ycles); all patients received four cycles of intravenous pemetrexed (500 mg/m(2)) with carboplatin (5

251 ne of three treatments: (1) VSG plus routine intravenous peri-operative antibiotics (n = 12), (2) VSG

252 sed or web-based response system, to receive intravenous pertuzumab (840 mg loading dose, followed by

253 pertuzumab serum C(trough) concentrations to intravenous pertuzumab plus trastuzumab in the neoadjuva

254 ombination for subcutaneous injection versus intravenous pertuzumab plus trastuzumab in the per-proto

255 izumab was achieved by means of an identical intravenous placebo, and blinding for vemurafenib was ac

256 ents with acute ischemic stroke (AIS) during intravenous r-tPA therapy and associated CA with respons

257 AIS patients eligible for intravenous r-tPA therapy were recruited.

258 ages were taken from rats over 240 min after intravenous radiotracer bolus injection.

259 nts were randomly assigned in a 2:1 ratio to intravenous remdesivir (200 mg on day 1 followed by 100

260 of enzymatic spectrum but are limited to the intravenous route of administration.

261 The intravenous route showed dose dependent dissemination of

262 This recombinant RRV was infectious by the intravenous route, established persistent infection in t

263 inhalation administration including oral and intravenous routes.

264 Placebo was administered as intravenous saline followed by sham injections.

265 Intravenous self-administration (IVSA) of various doses

266 herapeutic vaccination also reduced fentanyl intravenous self-administration in rats.

267 thylphenidate, but not modafinil, maintained intravenous self-administration in Sprague-Dawley rats s

268 udy compared the cardioprotective effects of intravenous statin administration during myocardial infa

269 administration route) were used for oral and intravenous studies.

270 ministration, with a median intraarterial-to-intravenous SUV(max) ratio of 0.81 (range, 0.36-2.09) on

271 participants (8.6%), an urgent HF visit with intravenous therapy in 20 (0.4%), HF hospitalization in

272 us access devices (CVAD) are used to deliver intravenous therapy to the bloodstream.

273 to oral therapy while 1285 (59%) remained on intravenous therapy.

274 Intravenous third-line anaesthetic agents are typically

275 (DOACs) with stroke severity, utilization of intravenous thrombolysis (IVT), safety of IVT, and 3-mon

276 y advanced, with rapid reperfusion by use of intravenous thrombolysis and endovascular thrombectomy s

277 The proportion of patients receiving intravenous thrombolysis with door-to-needle times 45 mi

278 Intravenous thrombolysis with tenecteplase improves repe

279 nts and immediate thrombectomy for LVO after intravenous thrombolysis, and (c) CT angiography for all

280 r all and best medical management (including intravenous thrombolysis, with rescue thrombectomy for p

281 covery (FLAIR) estimates lesion age to guide intravenous thrombolysis.

282 The benefit of intravenous thrombolytic therapy for acute ischemic stro

283 care beneficiaries aged >=65 years receiving intravenous thrombolytic treatment for acute ischemic st

284 Intravenous tissue plasminogen activator has been a corn

285 th gram-negative bloodstream infections from intravenous to oral therapy impact 30-day mortality?" We

286 ound Guidelines recommend against the use of intravenous tPA (tissue-type plasminogen activator; IV t

287 were treated for acute ischemic stroke with intravenous tPA within 4.5 hours from the time they were

288 Door-to-needle times for intravenous tPA.

289 , followed by 420 mg maintenance doses) plus intravenous trastuzumab (8 mg/kg loading dose, followed

290 administered on days 1-21 of a 21-day cycle, intravenous trastuzumab 8 mg/kg on cycle 1 day 1, follow

291 mergent/urgent heart failure visit requiring intravenous treatment (415 versus 519 patients; empaglif

292 perties to warrant further development as an intravenous treatment for COVID-19.

293 We hypothesized that the intravenous use of daptomycin generates off-target selec

294 Intravenous vaccination (SNP-IV) induced a higher propor

295 operative antibiotics (n = 12), (2) VSG with intravenous vancomycin chosen for its low intestinal pen

296 Intravenous vancomycin mono-therapy does not increase th

297 2-week risk of AKI after at least 3 days of intravenous vancomycin mono-therapy initiated within 5 d

298 have a less optimal hemodynamic response to intravenous vasodilator.

299 d included double-sequential defibrillation, intravenous versus intraosseous route for drug administr

300 um C(trough) subcutaneous to serum C(trough) intravenous was 1.22 (90% CI 1.14-1.31).